# Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female

> **NCT05426148** · PHASE4 · COMPLETED · sponsor: **Xiamen Innovax Biotech Co., Ltd** · enrollment: 540 (actual)

## Conditions studied

- Cervical Intraepithelial Neoplasia
- Cervical Cancer
- Vaginal Intraepithelial Neoplasia
- Vulvar Intraepithelial Neoplasia
- Persistent Infection

## Interventions

- **BIOLOGICAL:** Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®

## Key facts

- **NCT ID:** NCT05426148
- **Lead sponsor:** Xiamen Innovax Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-01
- **Primary completion:** 2020-08-01
- **Final completion:** 2021-04-30
- **Target enrollment:** 540 (ACTUAL)
- **Last updated:** 2022-06-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05426148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05426148, "Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05426148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*